

DISCLOSURE OF INFORMATION TO SHAREHOLDERS OF
PT SARANA MEDITAMA METROPOLITAN Tbk. ("**COMPANY**")
IN RELATION TO CAPITAL INCREASE PLAN WITH PRE-EMPTIVE RIGHTS ("**PRE-EMPTIVE
RIGHTS**")

THE INFORMATION AS CONTAINED IN THIS DISCLOSURE OF INFORMATION IS IMPORTANT
TO BE READ AND NOTICE OF THE COMPANY'S SHAREHOLDERS TO MAKE A DECISION ON
CAPITAL INCREASE PLAN WITH PRE-EMPTIVE RIGHTS

THIS DISCLOSURE OF INFORMATION MADE ON 16 OCTOBER 2020 ("**DISCLOSURE OF
INFORMATION**") TO CONDUCT CAPITAL INCREASE PLAN WITH PRE-EMPTIVE RIGHTS TO THE
COMPANY'S SHAREHOLDERS IN COMPLIANCE WITH FINANCIAL SERVICES
AUTHORITY/OTORITAS JASA KEUANGAN ("**OJK**") REGULATION NO. 32/POJK.04/2015 ON
CAPITAL INCREASE PLAN FOR PUBLIC COMPANY WITH PRE-EMPTIVE RIGHTS AS AMENDED BY
OJK REGULATION NO. 14/POJK.04/2019 YEAR 2019 ON AMENDMENT TO OJK REGULATION
NUMBER 32/POJK.04/ 2015 ON CAPITAL INCREASE PLAN FOR PUBLIC COMPANY WITH PRE-
EMPTIVE RIGHTS ("**POJK 32/2015**").



PT Sarana Meditama Metropolitan Tbk (SAME)
Domiciled in East Jakarta

Business Activities:

Private Hospital Activity with Practical Activities of General Practitioners, Specialists,
Dentists and Special Transportation for the Transport of Sick People

Head Office
Jl. Pulomas Barat VI No. 20
Kayu Putih, Pulo Gadung,
East Jakarta 13210
Indonesia
Tel. (021) 29779999
Fax. (021) 53129216
Email: corsec@omni-hospitals.com

The Extraordinary General Meeting of Shareholders ("**EGMS**") of the Company will be held
on 24 November 2020 in order to approve the capital increase plan by with Pre-Emptive
Rights to the Company's shareholders.

All information contained in this Disclosure of Information is only a recommendation,
subject to the approval of the EGMS and Prospectus issued in the context of capital increase
with Pre-Emptive Rights.

THIS DISCLOSURE OF INFORMATION AND THE INFORMATION CONTAINED IN IT IS NOT
INTENDED AS A PUBLIC OFFERING DOCUMENT OR RECOMMENDATION TO BUY, EITHER
DIRECTLY OR INDIRECTLY, OF THE COMPANY'S SECURITIES.

INFORMATION RELATING TO THE CAPITAL INCREASE WITH PRE-EMPTIVE RIGHTS

In connection with the Company's capital increase plan with Pre-Emptive Rights in this Disclosure of Information, the Company intends to issue a maximum of 10,300,000,000 (ten billion three hundred million) new shares of the Company with a nominal value of Rp 20 (twenty rupiah) per share ("**New Shares**").

These New Shares will be issued from the Company's portfolio shares and will be listed on the Indonesia Stock Exchange ("**IDX**") in accordance with the prevailing laws and regulations, including the Indonesian Stock Exchange Regulation No. IA regarding the Registration of Shares and Equity Securities Other Than Shares, Issued by the Listed Company, as last amended based on the Attachment to the Decree of the Directors of PT BEI No. Kep-00183/BEI/12-2018 dated 26 December 2018. These New Shares have the same and equal rights in all respects including the right to dividends with other shares of the Company.

In accordance with POJK 32/2015, the implementation of capital increase with Pre-Emptive Rights is subject to:

1. The approval from the Company's shareholders at the EGMS in connection with the capital increase with Pre-Emptive Rights; and
2. The submission of the Registration Statement by the Company to OJK in connection with the plan to the capital increase with Pre-Emptive Rights is declared effective by the OJK.

For the avoidance of doubt, the Company has the right to issue part or all of the maximum number of shares approved for issuance based on the resolution of the EGMS. It is the plan that the payment for shares to the capital increase plan with Pre-Emptive Rights will be made in the form of money.

Other provisions relating to the capital increase plan with Pre-Emptive Rights, including the final exercise price of the Pre-Emptive Rights and the final amount of the New Shares to be issue as well as other important information, will be disclose in the Prospectus issue in the context of capital in crement, which will be made available to shareholders entitled in due time, in accordance with applicable regulations.

ESTIMATED TIME OF CONDUCTING CAPITAL INCREASE

In accordance with POJK 32/2015, the Company will submit a Registration Statement in relation with the capital increase with Pre-Emptive Rights to OJK after obtaining approval from the EGMS which will be held on November 24, 2020 to approve the plan of the Company's capital increase with Pre-Emptive Rights, and the capital increase with Pre-Emptive Rights will be conducted after the Registration Statement is declared effective by the OJK.

Referring to the provisions of Article 8 paragraph 3 POJK 32/2015, the period between the date of approval by the EGMS and the effectiveness of the Registration Statement is not more than 12 (twelve) months.

OUTLINE ESTIMATES OF THE USE OF FUNDS

The Company plans to use the funds received from the capital increase with Pre-Emptive Rights (after deducting all commissions, costs, fees and other expenses) (i) for business expansion and investment, one of which is through the takeover of companies related to hospital business activities, namely PT Elang Medika Corpora, which is a Material Transaction as referred to in OJK Regulation No. 17 / POJK.04 / 2020 concerning Material Transactions and Changes in Business Activities ("**POJK No. 17/2020**") whereby the Company will carry out its obligations in accordance with POJK No. 17/2020; and / or (ii) for working capital purposes by the Company and / or its subsidiaries. The management of the Company has the right to adjust the use of funds by considering the circumstances and other factors deemed appropriate.

Further information regarding the Company's plan to take over PT Elang Medika Corpora will also disclosed in the Disclosure of Information regarding material transaction plans in order to comply with POJK No. 17/2020 announced by the Company on the same date as the date of this Disclosure of Information.

Final information regarding the use of the funds will be disclosed in the prospectus issued in the context of the capital increase with Pre-Emptive Rights which will be made available to shareholders in time, in accordance with applicable laws and regulations.

EFFECTS CAPITAL INCREASE ON FINANCIAL CONDITIONS AND SHAREHOLDERS

Effects to the Company

The capital increase with Pre-Emptive Rights plan is to strengthen the Company's capital structure to increase the Company's ability to improve and develop its business activities and competitiveness to support the Company's long-term growth. In line with the growth of business activities, the Company's performance is expected to increase and provide positive value for the Company's shareholders. In addition, the benefits of the plan to take over PT Elang Medika Corpora are also expected to (i) develop business and realize the Company's vision to become the leading hospital group in providing the best healthcare services according to the needs of each patient, more efficiently so as to maximize the Company's expansion opportunities, (ii) strengthen the capital structure of the Company so that further operation of hospitals the Company is expected to provide superior health services with international standards, (iii) increase the Company's future profits, and (iv) increase the attractiveness of the Company's investment value.

Effects to the shareholders of the Company

Through conducting capital increase with Pre-Emptive Rights, the Company's shareholders not using their Pre-Emptive Rights will be subjected to dilution of the percentage of share ownership in the Company up to a maximum of 63.58% (sixty three point fifty eight percent) if all of the Pre-Emptive Rights issued by the Company are exercised by the entitled Pre-Emptive Rights holders.

ADDITIONAL INFORMATION

The capital increase with Pre-Emptive Rights will be carried out after obtaining the EGMS approval and the effective statement from the OJK on the Registration Statement submitted by the Company in relation with the additional capital by granting this Pre-Emptive Rights.

To obtain additional information regarding the above matter, please contact the Company during working hours at the following address:

PT Sarana Meditama Metropolitan Tbk (SAME)

Head Office:

Jl. Pulomas Barat VI No. 20

Kayu Putih, Pulo Gadung,

Jakarta Timur 13210

Indonesia

Telp. (021) 29779999

Fax. (021) 53129216

Email: corsec@omni-hospitals.com